STOCK TITAN

CV SCIENCES INC - CVSI STOCK NEWS

Welcome to our dedicated page for CV SCIENCES news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on CV SCIENCES stock.

CV Sciences, Inc. (CVSI) is a consumer wellness company dedicated to improving health through the integration of science and nature. Specializing in hemp extracts and science-backed natural ingredients, CV Sciences offers a range of products such as hemp extracts, softgels, and plant-based foods. The company's commitment to consumer well-being is evident in its mission to make healthy people healthier. With a focus on research-supported, plant-based alternatives, CV Sciences aims to provide high-quality products that cater to the well-being of both humans and pets. The recent launch of +PlusCBD™ Pet wellness treats, including the Pet Hip and Joint Health Chews and Pet Calming Care Chews, showcases CV Sciences' dedication to innovation and safety, validated by the National Animal Supplement Council (NASC). These premium CBD-infused chews, designed to support pet health, are crafted using organic hemp-derived CBD and a blend of antioxidants, anti-inflammatory agents, and essential supplements. The safety, efficacy, and quality of each product are ensured through rigorous testing by independent laboratories, aligning with NASC's stringent standards.

CV Sciences' strategic acquisitions, such as Elevated Softgels, further enhance its operational capabilities, allowing for in-house manufacturing and new product development. By leveraging Elevated Softgels' manufacturing expertise, CV Sciences aims to streamline production, increase operational efficiency, and expand its product offerings. The company's financial performance reflects its resilience and growth trajectory, with sequential revenue increases, improved gross margins, and strategic investments driving long-term value creation. As CV Sciences continues to innovate and expand its product portfolio, it remains committed to delivering science-backed, plant-based solutions that promote holistic well-being.

Rhea-AI Summary

CV Sciences, Inc. (OTCQB: CVSI) announced preliminary approval of a proposed settlement regarding six shareholder derivative lawsuits related to allegations of misleading investors concerning patent protection for CVSI-007. The lawsuits arose from a tweet by Citron Research on August 20, 2018. The proposed settlement will involve payment of $275,000 in attorneys' fees, expected to be covered by insurance. The final approval is pending a court hearing on November 14, 2022. All claims will be resolved without admission of wrongdoing by the Company or defendants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences, Inc. (OTCQB:CVSI) announced the complete retirement of its convertible debt, strengthening its balance sheet and eliminating the dilutive impact on shareholders. CEO Joseph Dowling emphasized that this move will alleviate downward pressure on CVSI stock, allowing the company to focus on enhancing shareholder value and expanding its PlusCBD™ branded product line. This strategic decision was detailed in a Current Report on Form 8-K filed with the SEC on August 25, 2022. For more information, visit www.cvsciences.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
none
-
Rhea-AI Summary

CV Sciences reported its first-quarter 2022 financial results, recording revenue of $4.4 million, down 8% from $4.8 million in Q1 2021. The gross margin dropped to 26.0% compared to 32.4% in Q4 2021. However, the total cash balance increased to $2.4 million from $1.4 million at year-end 2021. The company launched several new OTC pain relief products and claimed $2.0 million in employee retention credits. Although sales volume increased 3%, it was offset by higher discounts, resulting in an operating loss reduction to $1.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

CV Sciences (OTCQB:CVSI) will release its first quarter financial results on May 16, 2022, before market open. The company, known for manufacturing hemp CBD products, will hold a conference call at 7:00 a.m. PT (10:00 a.m. ET) to discuss the results. Investors can participate via phone or access a webcast available on their Investor Relations website.

CV Sciences operates in two segments: consumer products and drug development, with PlusCBD™ being a leading brand in the hemp-derived CBD market. The company adheres to Good Manufacturing Practices and supports product efficacy through clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

CV Sciences reported a 2021 revenue of $20.0 million, down 18% from $24.4 million in 2020. The gross margin decreased to 43.0% from 45.1%, with a total cash balance of $1.4 million, down from $4.5 million. Despite these challenges, retail distribution grew to over 8,400 stores and operating losses reduced to $18.4 million. CV Sciences introduced several new products, including the clinical strength ProCBD™ line, aiming for future growth amid competitive pressures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
-
Rhea-AI Summary

CV Sciences, a leading manufacturer of hemp CBD products, announced it will disclose its financial results for Q4 and full year 2021 on March 31, 2022, after market close. A conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day, available via webcast on their Investor Relations website. Investors can listen live or access a replay through specific phone numbers provided. The company operates in two segments: consumer products for dietary supplements and drug development focused on CBD therapeutics, with products sold in over 8,400 retail locations across the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

CV Sciences announces the launch of +PlusCBD Relief Softgels, delivering seven times more CBDA and CBD than the original formula. These softgels include Levagen®+ PEA, an alternative to ibuprofen, promoting a healthy inflammatory response and aiding in managing occasional soreness. CEO Joseph Dowling emphasizes the product's safety and effectiveness, contributing to the company's mission of innovative health solutions. +PlusCBD products are widely available, sold at over 8,400 retail locations in the U.S., reinforcing CV Sciences' position as a leading CBD brand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary

CV Sciences has launched new +PlusCBD Relief Softgels, featuring seven times more CBDA and CBD than its original formula. The softgels contain Levagen®+ PEA, shown in studies as an alternative to ibuprofen, promoting a healthy inflammatory response. CEO Joseph Dowling emphasized the product's purity and effectiveness in enhancing health and wellness. These softgels are available on the company's website and will soon be at select retailers. CV Sciences operates in dietary supplements and drug development, with its products sold at over 8,400 retail locations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary

CV Sciences has launched four new +PlusCBD™ Pain Relief topicals designed for targeted pain relief, featuring ingredients like camphor, menthol, and hemp-derived CBD. The new products include the Pain Relief Sport Recovery Stick, Pain Relief Penetrating Cream, Pain Relief Muscle Cream, and Pain Relief Arthritis Cream, each addressing specific types of discomfort. The company emphasizes a focus on consumer wellness and innovation, adhering to GMP guidelines. With products available in over 8,400 U.S. retail locations, CV Sciences aims to strengthen its position in the CBD market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

CV Sciences Announces Distribution Agreement with GNC

CV Sciences, Inc. (OTCQB: CVSI) has partnered with GNC to distribute its +PlusCBD™ products in 770 GNC locations across the U.S., starting early 2022. The product line includes various CBD items like Cherry Mango Gummies, Softgels, and Peppermint Liquid, reinforcing CV Sciences' commitment to quality and safety. This partnership reflects the favorable regulatory climate post-AB 45 in California and is a milestone in CV Sciences' distribution strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none

FAQ

What is the current stock price of CV SCIENCES (CVSI)?

The current stock price of CV SCIENCES (CVSI) is $0.0353 as of December 23, 2024.

What is the market cap of CV SCIENCES (CVSI)?

The market cap of CV SCIENCES (CVSI) is approximately 7.4M.

What products does CV Sciences offer?

CV Sciences specializes in hemp extracts, softgels, and plant-based foods, providing consumers with science-backed, natural alternatives for health and wellness.

What are some recent innovations by CV Sciences?

CV Sciences recently launched +PlusCBD™ Pet wellness treats, including the Pet Hip and Joint Health Chews and Pet Calming Care Chews, designed to support pet well-being with premium CBD-infused formulations.

How does CV Sciences ensure product quality and safety?

CV Sciences conducts rigorous testing of its products through independent laboratories to ensure purity, potency, and compliance with industry standards, such as those set by the National Animal Supplement Council (NASC).

What strategic acquisitions has CV Sciences made recently?

CV Sciences recently acquired Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures, to enhance its production capabilities, drive operational efficiency, and expand its product offerings.

What is CV Sciences' approach to innovation and growth?

CV Sciences focuses on continuous innovation, strategic investments, and in-house manufacturing to drive growth, increase market share, and provide consumers with high-quality, research-supported products for holistic well-being.

CV SCIENCES INC

OTC:CVSI

CVSI Rankings

CVSI Stock Data

7.37M
184.23M
0.02%
0%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
San Diego